• Mashup Score: 30

    Prosurvival tumor necrosis factor receptor (TNFR) superfamily (TNFRSF) members on T cells, including 4-1BB, CD27, GITR, and OX40, support T cell accumulation during clonal expansion, contributing to T cell memory. During viral infection, tumor necrosis factor superfamily (TNFSF) members on inflammatory monocyte-derived antigen-presenting cells (APCs) provide a postpriming signal (signal 4) for T cell accumulation, particularly in the tissues. Patients with loss-of-function mutations in TNFR/TNFSF members reveal a critical role for 4-1BB and CD27 in CD8 T cell control of Epstein-Barr virus and other childhood infections and of OX40 in CD4 T cell responses. Here, on the 20th anniversary of a previous Annual Review of Immunology article about TNFRSF signaling in T cells, we discuss the effects of endogenous TNFRSF signals in T cells upon recognition of TNFSF members on APCs; the role of TNFRSF members, including TNFR2, on regulatory T cells; and recent advances in the incorporation of TNF

    Tweet Tweets with this article
    • RT @LabWaggoner: Review @AnnualReviews TNF/TNFR Superfamily Members in Costimulation of T Cell Responses—Revisited https://t.co/LqqmrScvYV…

  • Mashup Score: 23
    ClinicalTrials.gov - 2 month(s) ago

    Hide glossary Study record managers: refer to the Data Element Definitions if submitting registration or results information.

    Tweet Tweets with this article
    • Excited to help lead Phase 2/3 frontline metastatic #melanoma TeLuRide-006 study of pembro +/- novel IV TLR7/8 agonist EIK1001. Super interesting pre-clinical & prelim responses in PD1 refractory dz. Trial is open in #Pittsburgh & globally for accrual! https://t.co/wfnUvAoKWO https://t.co/YPmxULeyL4

  • Mashup Score: 52
    ClinicalTrials.gov - 2 month(s) ago

    Hide glossary Study record managers: refer to the Data Element Definitions if submitting registration or results information.

    Tweet Tweets with this article
    • Amazing @sitcancer Spring Scientific on cell therapy in solid tumors! Appreciated op to discuss IMA203. One of the hottest agents in #melanoma & perhaps all of solid tumor oncology! Very excited that the SUPRAME Ph 3 study is now accruing pts! https://t.co/ZoillxHhV4 https://t.co/yzwEoFelp9

  • Mashup Score: 244

    Nature Medicine – In a non-prespecified interim analysis of a phase 1 trial, autologous PRAME-directed TCR T cell therapy was safe and elicited durable responses in patients with recurrent and/or…

    Tweet Tweets with this article
    • Extremely excited re: IMA203 - PRAME TCR T cells Ph 1 study published in @NatureMedicine! This is a transformative Rx in #melanoma for HLA-A201+ & PD1 refractory pts. Compared to TIL, easier to make, less toxic & so far ~2x response rate in heavily pre-Rx. https://t.co/HVgl1QRQfQ https://t.co/EPRliSoXbz

  • Mashup Score: 237

    Nature Medicine – In a non-prespecified interim analysis of a phase 1 trial, autologous PRAME-directed TCR T cell therapy was safe and elicited durable responses in patients with recurrent and/or…

    Tweet Tweets with this article
    • Extremely excited re: IMA203 - PRAME TCR T cells Ph 1 study published in @NatureMedicine! This is a transformative Rx in #melanoma for HLA-A201+ & PD1 refractory pts. Compared to TIL, easier to make, less toxic & so far ~2x response rate in heavily pre-Rx. https://t.co/HVgl1QRQfQ https://t.co/EPRliSoXbz